| Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 | International Journal of Cancer | 2010 | 12.1K |
| Cancer statistics, 2010 | Ca-A Cancer Journal for Clinicians | 2010 | 11K |
| Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 | Cancer Cell | 2010 | 4.8K |
| Drug combination studies and their synergy quantification using the Chou-Talalay method | Cancer Research | 2010 | 3.3K |
| Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial | Lancet Oncology, The | 2010 | 3.1K |
| Integrative genomic profiling of human prostate cancer | Cancer Cell | 2010 | 2.7K |
| Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group | Journal of Clinical Oncology | 2010 | 2.5K |
| Integrins in cancer: biological implications and therapeutic opportunities | Nature Reviews Cancer | 2010 | 2.5K |
| Delivering nanomedicine to solid tumors | Nature Reviews Clinical Oncology | 2010 | 2.3K |
| Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates | Journal of Clinical Oncology | 2010 | 2.2K |
| American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer | Journal of Clinical Oncology | 2010 | 2.1K |
| Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial | Journal of Clinical Oncology | 2010 | 1.9K |
| An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients | Breast Cancer Research and Treatment | 2010 | 1.9K |
| Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation | Cancer Cell | 2010 | 1.9K |
| EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer | Oncogene | 2010 | 1.9K |
| Global patterns of cancer incidence and mortality rates and trends | Cancer Epidemiology Biomarkers and Prevention | 2010 | 1.9K |
| Fibroblast growth factor signalling: from development to cancer | Nature Reviews Cancer | 2010 | 1.8K |
| Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma | Cancer Cell | 2010 | 1.8K |
| Epigenetics in cancer | Carcinogenesis | 2010 | 1.7K |
| Estimates of cancer incidence and mortality in Europe in 2008 | European Journal of Cancer | 2010 | 1.7K |
| Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis | Lancet Oncology, The | 2010 | 1.7K |
| Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study | Lancet Oncology, The | 2010 | 1.6K |
| The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate | Cancer Cell | 2010 | 1.5K |
| Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival | Lancet Oncology, The | 2010 | 1.5K |
| Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer | Breast Cancer Research | 2010 | 1.4K |
